Analysts Offer Insights on Healthcare Companies: SAGE Therapeutics (NASDAQ: SAGE), Spark Therapeutics (NASDAQ: ONCE) and Kite Pharma (NASDAQ: KITE)

By Ryan Adsit

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on SAGE Therapeutics (NASDAQ: SAGE), Spark Therapeutics (NASDAQ: ONCE) and Kite Pharma (NASDAQ: KITE) with bullish sentiments.

SAGE Therapeutics (NASDAQ: SAGE)

In a report released today, Ritu Baral from Cowen & Co. reiterated a Buy rating on SAGE Therapeutics (NASDAQ: SAGE), with a price target of $95. The company’s shares opened today at $38.71.

Baral wrote:

“This morning, SAGE reported 3Q16 results.”

According to TipRanks.com, Baral is a 2-star analyst with an average return of -0.3% and a 31.4% success rate. Baral covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Protalix Biotherapeutics, and Intra-Cellular Therapies.

Currently, the analyst consensus on SAGE Therapeutics is Strong Buy and the average price target is $65.50, representing a 69.2% upside.

In a report released today, Canaccord Genuity also reiterated a Buy rating on the stock with a $110 price target.
Spark Therapeutics (NASDAQ: ONCE)

Cowen & Co. analyst Phil Nadeau reiterated a Buy rating on Spark Therapeutics (NASDAQ: ONCE) today and set a price target of $75. The company’s shares opened today at $40.51.

Nadeau commented:

“Spark is well funded with $359MM in cash as of 9/30.”

According to TipRanks.com, Nadeau is a 1-star analyst with an average return of -3.1% and a 34.4% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Achillion Pharmaceuticals, Catabasis Pharmaceuticals, and Voyager Therapeutics Inc.

Spark Therapeutics has an analyst consensus of Moderate Buy.

Kite Pharma (NASDAQ: KITE)

In a report released today, Eric Schmidt from Cowen & Co. reiterated a Buy rating on Kite Pharma (NASDAQ: KITE). The company’s shares opened today at $40.01, close to its 52-week low of $38.41.

Schmidt observed:

“Kite will make at least four presentations at the 2016 ASH meeting, including data.”

According to TipRanks.com, Schmidt is a 5-star analyst with an average return of 11.6% and a 38.3% success rate. Schmidt covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals Inc, Merrimack Pharmaceuticals, and Threshold Pharmaceuticals.

Kite Pharma has an analyst consensus of Strong Buy.